. 2022 Apr 2;24(8):1071–1079. doi: 10.1007/s11912-022-01243-x

Table 2.

Primary and secondary efficacy endpoints

	PFS (months)	ORR (%)	DOR (months)	OS at 24 months (%)
KEYNOTE-022
Dabrafenib + trametinib + pembrolizumab vs Dabrafenib + trametinib + placebo	16.9 10.7 (HR 0.53)	63.3 71.7	25.1 12.1	63 52
IMspire150
Vemurafenib + cobimetinib + atezolizumab vs Vemurafenib + cobimetinib + placebo	15.1 10.6 (HR 0.78, p = 0.0249)	66.3 65.0	21.0 12.6	60.4 53.1
COMBI-i
Dabrafenib + trametinib + spartalizumab vs Dabrafenib + trametinib + placebo	16.2 12.0 (HR 0.82, p = 0.042)	68.5 64.2	NR 20.7	68 62

PFS
(months)

ORR
(%)

DOR
(months)

OS at 24 months
(%)

KEYNOTE-022

Dabrafenib + trametinib + pembrolizumab vs

Dabrafenib + trametinib + placebo

16.9

10.7 (HR 0.53)

63.3

71.7

25.1

12.1

IMspire150

Vemurafenib + cobimetinib + atezolizumab vs

Vemurafenib + cobimetinib + placebo

15.1

10.6 (HR 0.78, p = 0.0249)

66.3

65.0

21.0

12.6

60.4

53.1

COMBI-i

Dabrafenib + trametinib + spartalizumab vs

Dabrafenib + trametinib + placebo

16.2

12.0 (HR 0.82, p = 0.042)

68.5

64.2

20.7

PFS, median progression-free survival (months); HR, hazard ratio; ORR, objective response rate (%); DOR, duration of response (months); OS, overall survival (%)